Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + bendamustine first-line study in newly diagnosed CLL/SLL
ChiCTR2300068152Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Feb 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zanubrutinib and bendamustine in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Ruijin Hospital. Primary endpoints: complete response rate, progression-free survival and 2 more. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
zanubrutinibbendamustine
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ChiCTR2300068152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068152.